Mounjaro (Tirzepatide) | Diabetes & Weight Loss Medication
Table of contents
As of now, Mounjaro (Tirzepatide) is fully approved by the Thai FDA and distributed via licensed clinic and hospital. Whether you’re exploring Mounjaro for its dual benefits or starting a prescription-based weight loss plan, H.U.M. Clinic, a leading Weight Loss clinic in Bangkok, provides expert consultation and personalized treatment to help you reach your health and wellness goals.

What is Mounjaro (Tirzepatide)?
Overview of Mounjaro
How does Mounjaro work?
Mounjaro | Medical Uses
Type 2 Diabetes Management
Mounjaro as Weight Loss Treatment
Mounjaro | Dosage and Administration
Recommended Dosages of Mounjaro
- The typical starting dose is 2.5 mg once weekly.
- Doses is usually titrated up once every 4 weeks.
- Doses can be titrated to 5 mg, 7.5mg, 10 mg, 12mg, or 15 mg weekly
- The 15 mg is the maximum dose.
- The dose is gradually increased based on individual tolerance and treatment goals.
Mounjaro | Administration Instructions
Mounjaro | Safety and Precautions
- A personal or family history of MTC (Medullary Thyroid Carcinoma) or MEN 2 (Multiple Endocrine Neoplasia syndrome type 2).
- Known allergies to any component of Mounjaro.
- Individuals with type 1 diabetes
- Children under 18 years.
- Are pregnant, plan to become pregnant, or are breastfeeding.
- Have a history of pancreatitis, kidney issues, or severe stomach problems like gastroparesis.
- Take medications that affect blood sugar, including insulin or sulfonylureas.
- Use oral birth control pills, as Mounjaro may reduce their effectiveness. Alternative contraception is recommended for at least four weeks after starting or adjusting Mounjaro doses.
Mounjaro | Side Effects
Common Side Effects
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Indigestion
- Abdominal pain
Serious Side Effects
- Thyroid Tumors: Mounjaro has been associated with thyroid tumors, including thyroid cancer. If you notice a lump, swelling in the neck, hoarseness, trouble swallowing, or shortness of breath, contact your doctor immediately. Avoid Mounjaro if you or a family member has a history of MTC or MEN 2.
- Pancreatitis: Stop use and seek medical attention if you experience severe, persistent abdominal pain that may radiate to your back, with or without vomiting.
- Hypoglycemia (Low Blood Sugar): If combined with insulin or sulfonylureas, Mounjaro may increase the risk of low blood sugar, causing dizziness, sweating, and weakness.
- Gallbladder Problems: Symptoms such as pain in the upper abdomen, yellowing of the skin or eyes, and clay-colored stools should be reported promptly.
- Kidney Problems: Dehydration from nausea, vomiting, or diarrhea may worsen kidney function. Ensure proper hydration during treatment.
- Vision Changes: Notify your provider if you experience changes in vision.
Mounjaro vs. Other GLP-1 Medications
Mounjaro vs. Semaglutide (Ozempic, Wegovy)
Mounjaro vs. Liraglutide (Victoza, Saxenda)

Why Choose H.U.M. Clinic for Mounjaro?
FDA-Approved Medication
Expert Care and Monitoring
Comprehensive Support

FAQ About Mounjaro
While Tirzepatide is not officially approved for prediabetes, its ability to regulate blood sugar levels and improve insulin sensitivity makes it a promising option for early intervention. Consult a healthcare provider for personalized advice.
Yes, Tirzepatide can be combined with other diabetes treatments like metformin or insulin. However, combining therapies may increase the risk of hypoglycemia (low blood sugar), so monitoring and adjustments by a doctor are essential.
Tirzepatide has shown potential benefits for cardiovascular health by aiding weight loss and improving metabolic profiles. However, patients with a history of heart disease should consult their doctor to evaluate potential risks.
Discontinuing the medication may lead to weight regain. Long-term use may be required to maintain results. Always discuss any changes to your treatment plan with your healthcare provider.
Tirzepatide should be stored in the refrigerator at 2°C to 8°C (36°F to 46°F). After first use, it can be stored as unrefrigerated below 30°C (86°F) for up to 30 days. Discard the pen 30days after first use.
Tirzepatide is not recommended for individuals with a history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or severe gastroparesis. Always consult your doctor before starting treatment.
Wichakorn Jitpraphun, M.D. (Dr. Kamin) is the Co-founder and Medical Director of H.U.M. Clinic, Bangkok. A physician licensed by the Medical Council of Thailand (License No. 51754), he has over 10 years of clinical experience, practicing since 2016. Dr. Kamin holds Certificate Diplomas in Sexual Medicine and Sexology from Thammasat University and Andrology certification from the Society of Men’s Health Singapore. His clinical practice focuses on testosterone replacement therapy (TRT), Men’s health, sexual medicine, HIV prevention and treatment, peptide therapy, and evidence-based medical weight management.